Polaris Market Research today announced findings from its latest report, projecting the global Oligonucleotide Synthesis market to grow from USD 3.55 billion in 2025 to USD 12.49 billion by 2034, at a CAGR of 15.01% from 2026 to 2034. The report profiles 14 leading companies across five market segmentation categories.

Analyst Commentary on Oligonucleotide Synthesis Market Growth

“Market growth is being driven by an expanding pipeline of RNA-based medicines and a clear shift toward outsourced oligonucleotide synthesis, purification and manufacturing services,” said analysts at Polaris Market Research. “Companies that invest early in automation, enzymatic synthesis and GMP-scale capacity are best placed to capture the opportunity, particularly as Asia Pacific scales up its biotechnology and genomics activity.”

Oligonucleotide Synthesis Market Statistics at a Glance

●       2025 Market Size: USD 3.55 billion

●       2034 Projected Size: USD 12.49 billion

●       CAGR (2026-2034): 15.01%

●       Largest Region (2025): North America, 40.9% share

Key Growth Drivers, Major Companies and Segments Covered

Growth Drivers: Rising demand for oligonucleotide-based medicines, growing investment in advanced manufacturing capacity, and wider use of synthesized oligos in molecular diagnostics and genetic testing are the primary forces behind the market’s expansion, alongside growing demand for RNA therapeutics and gene editing tools. In 2026, Aragen Life Sciences announced plans to add 500 kiloliters of new CDMO capacity, with oligonucleotides among its focus areas.

Major Companies Covered: Agilent Technologies, Inc., Thermo Fisher Scientific Inc., Merck KGaA, GenScript Biotech Corporation, Twist Bioscience Corporation.

Segments Covered: By Product (Synthesized Oligonucleotide Products, Equipment, Reagents, Services), By Application (PCR Primers, PCR Assays and Panels, Sequencing, Antisense Oligonucleotides), By End User, By Technology/Chemistry, By Region. Services led with a 38.24% share in 2025, while antisense oligonucleotides are projected to grow at a 15.9% CAGR through 2034.

Recent Developments in the Oligonucleotide Synthesis Market

●       July 2026: DNA Script signed a distribution agreement with Imperial Life Sciences to expand access to its SYNTAX on-demand DNA synthesis platform in India.

●       July 2026: Oligo Factory launched NGS Unique-Dual Indexed Stubby Adapter Kits to support next-generation sequencing workflows.

●       2026: Agilent launched Agilent Advanced Therapeutics to unify its CDMO capabilities, including oligonucleotide manufacturing, across North America.

Read More @ https://www.polarismarketresearch.com/industry-analysis/oligonucleotide-synthesis-market

Regional Snapshot: North America Leads, Asia Pacific Fastest-Growing

North America led with a 40.9% share in 2025, supported by a strong pharmaceutical and biotechnology base, substantial R&D investment and growing genomics and gene therapy initiatives, while Asia Pacific is projected to register the fastest CAGR of 17.5% through 2034 on the back of rising biotechnology investment, genetic testing demand and personalized medicine research.

Why It Matters for Buyers Comparing Top Oligonucleotide Synthesis Companies

For stakeholders researching the oligonucleotide synthesis market forecast 2034 and the top oligonucleotide synthesis companies, the underlying report benchmarks Oligonucleotide Synthesis market share, company positioning, and segment-level forecasts to support sourcing, partnership, and investment decisions through 2034.

More Trending Latest Reports By Polaris Market Research:

green-hydrogen-market

coolant-distribution-unit-market

music-streaming-market

air-purifier-market

lithium-carbonate-market

australia-bubble-tea-market

high-speed-camera-market

hydrocolloids-market

smart-sports-equipment-market